Journal article

Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma

Xiaolei Zhou, Jianmin Wang, Jessica Zhang, Catherine Copley-Merriman, Yasuhiro Torigoe, Carolina Reyes, John F Seymour, Fritz C Offner, Marek Trneny, Gilles Andre Salles

HEMATOLOGY | MANEY PUBLISHING | Published : 2015

Abstract

OBJECTIVES: The randomized phase 3 PRIMA trial established that 2 years of rituximab maintenance therapy after attaining disease response to immunochemotherapy as first-line treatment of follicular lymphoma, reduced the risk of disease progression, compared with observation, without adversely affecting patient-reported quality of life (QoL). We now report additional analyses of symptom burden and toxicity. METHODS: Symptom burden was measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items. The proportion of patients with worsening, no change, or improvement in symptoms from maintenance baseline was compared between rituximab main..

View full abstract